Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda(R) (memantine HCl) at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD). (Source: Alzheimer’s / Dementia News From Medical News Today)
(Source: Evidence-Based Mental Health)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
Results Presented at ICAD 2008 Highlight Significant Improvement in Cognitive Performance and Global Clinical Status in Patients with Alzheimer’s Disease CHICAGO, July 30 (HSMN NewsFeed) — Forest Laboratories, Inc. (NYSE: FRX ) presented today positi… Biopharmaceuticals, NeurologyForest Laboratories, Namenda, memantine, Alzheimer’s Disease (Source: HSMN NewsFeed)
- Results Presented at ICAD 2008 Highlight Significant Improvement in Cognitive Performance and Global Clinical Status in Patients with Alzheimer’s Disease -
CHICAGO, July 30, 2008 /PRNewswire-FirstCall/ — Forest Laboratories, Inc. presented today… (Source: Drugs.com – Clinical Trials)
GREENBELT, Md. – A woman who claims that her husband’s use of Zoloft and trazodone caused him to commit suicide and the manufacturers of the drug agreed to stay the case pending the outcome of mediation proceedings scheduled for Aug. 21 (Michelle P. LaBaer v. Pfizer Inc., et al., No. 08-CV-959, D. Md.; See March 2008, Page 18). Full story on lexis.com (Source: LexisNexis® Mealey’s™ Antidepressant Drugs Legal News)
Following on from our hugely successful iPhone edition for healthcare professionals, the long anticipated consumer version is now available. Includes predictive search and consumer focused information – all designed to work perfectly on the iPhone.
Simly go to www.drugs.com (on your iPhone or iPod Touch) to get started.
Windows Mobile and Blackberry compatible editions are also on [...]
In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors. (Source: News-Medical News Feed)
HIV-positive women may be reluctant to attend gynaecology or family planning clinics for fear of divulging their condition. Therefore, a referral clinic was opened within the HIV clinic. Retrospective case-note reviews of 197 new patients revealed 109 with a variety of medical gynaecology conditions (menorrhagia being the commonest) and 88 sought contraception. The full range of contraceptives was used, including Mirena for the treatment of menorrhagia as well as contraception and the combined pill adjusted for interaction with liver enzyme-inducing antiretroviral drugs. The acceptance of contraceptive advice and gynaecological evaluation by the patients has resulted in improved reproductive health services for these HIV-positive women. In centres with large cohorts of HIV-positive women, …
Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for TOPAMAXî (topiramate), based on studies submitted in response to a Written Request by the FDA to investigate the use of TOPAMAX in pediatric patients aged 1 to 24 months with partial onset seizures. (Source: Health News from Medical News Today)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
Conclusion:
Proper evaluation of irregular vaginal bleeding, including cervical cytology, should be a prerequisite among all women opting for a Mirena(R) and must be repeated in case of persisting symptoms. (Source: BioMed Central)